关于Asciminib在德国慢性期费城染色体阳性慢性髓性白血病患者中的耐受性、安全性和有效性研究 (ASC2ADHERE)
一项在德国新诊断和已接受过治疗的费城染色体阳性慢性期慢性髓性白血病患者中评价Asciminib的耐受性、安全性和有效性的非干预性研究——ASC2ADHERE研究
The aim of this study is to assess the real-world effectiveness of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) patients who were either newly diagnosed or previously treated with one ATP-competitive tyrosine kinase inhibitor (TKI).
研究概览
地位
条件
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Novartis Pharmaceuticals
- 电话号码:+41613241111
- 邮箱:novartis.email@novartis.com
研究联系人备份
- 姓名:Novartis Pharmaceuticals
学习地点
-
-
-
Amberg、德国、92224
- 招聘中
- Novartis Investigative Site
-
Bad Friedrichshall、德国、74177
- 招聘中
- Novartis Investigative Site
-
Bad Liebenwerda、德国、04924
- 招聘中
- Novartis Investigative Site
-
Bad Saarow、德国、15526
- 招聘中
- Novartis Investigative Site
-
Berlin、德国、10437
- 招聘中
- Novartis Investigative Site
-
Berlin、德国、10365
- 招聘中
- Novartis Investigative Site
-
Berlin、德国、12552
- 招聘中
- Novartis Investigative Site
-
Berlin、德国、10559
- 招聘中
- Novartis Investigative Site
-
Berlin、德国、12487
- 招聘中
- Novartis Investigative Site
-
Bremerhaven、德国、27568
- 招聘中
- Novartis Investigative Site
-
Buchholz Nordheide、德国、21244
- 招聘中
- Novartis Investigative Site
-
Cottbus、德国、03046
- 招聘中
- Novartis Investigative Site
-
Deggendorf、德国、94469
- 招聘中
- Novartis Investigative Site
-
Detmold、德国、32756
- 招聘中
- Novartis Investigative Site
-
Dorfen、德国、84405
- 招聘中
- Novartis Investigative Site
-
Dortmund、德国、44263
- 招聘中
- Novartis Investigative Site
-
Dresden、德国、01307
- 招聘中
- Novartis Investigative Site
-
Dresden、德国、01127
- 招聘中
- Novartis Investigative Site
-
Düren、德国、52353
- 招聘中
- Novartis Investigative Site
-
Erfurt、德国、99085
- 招聘中
- Novartis Investigative Site
-
Erfurt、德国、99084
- 招聘中
- Novartis Investigative Site
-
Eschweiler、德国、52249
- 招聘中
- Novartis Investigative Site
-
Göttingen、德国、37073
- 招聘中
- Novartis Investigative Site
-
Hanover、德国、30161
- 招聘中
- Novartis Investigative Site
-
Hanover、德国、30625
- 招聘中
- Novartis Investigative Site
-
Hildesheim、德国、31135
- 招聘中
- Novartis Investigative Site
-
Kiel、德国、24105
- 招聘中
- Novartis Investigative Site
-
Leipzig、德国、04103
- 招聘中
- Novartis Investigative Site
-
Leverkusen、德国、51375
- 招聘中
- Novartis Investigative Site
-
Mutlangen、德国、73557
- 招聘中
- Novartis Investigative Site
-
Naunhof、德国、04683
- 招聘中
- Novartis Investigative Site
-
Neuss、德国、41462
- 招聘中
- Novartis Investigative Site
-
Offenburg、德国、77654
- 招聘中
- Novartis Investigative Site
-
Oldenburg、德国、26121
- 招聘中
- Novartis Investigative Site
-
Parchim、德国、19370
- 招聘中
- Novartis Investigative Site
-
Potsdam、德国、14467
- 招聘中
- Novartis Investigative Site
-
Potsdam、德国、14482
- 招聘中
- Novartis Investigative Site
-
Schorndorf、德国、73614
- 招聘中
- Novartis Investigative Site
-
Schwetzingen、德国、68723
- 招聘中
- Novartis Investigative Site
-
Soest、德国、59494
- 招聘中
- Novartis Investigative Site
-
Stade、德国、21680
- 招聘中
- Novartis Investigative Site
-
Torgau、德国、04860
- 招聘中
- Novartis Investigative Site
-
Ulm、德国、89081
- 招聘中
- Novartis Investigative Site
-
Wetzlar、德国、35578
- 招聘中
- Novartis Investigative Site
-
-
Baden-Wurttemberg
-
Baden-Baden、Baden-Wurttemberg、德国、76532
- 招聘中
- Novartis Investigative Site
-
Heidenheim、Baden-Wurttemberg、德国、89522
- 招聘中
- Novartis Investigative Site
-
Schwäbisch Hall、Baden-Wurttemberg、德国、74523
- 招聘中
- Novartis Investigative Site
-
Winnenden、Baden-Wurttemberg、德国、71364
- 招聘中
- Novartis Investigative Site
-
-
Bavaria
-
Aschaffenburg、Bavaria、德国、63739
- 招聘中
- Novartis Investigative Site
-
Augsburg、Bavaria、德国、86152
- 招聘中
- Novartis Investigative Site
-
Donauwörth、Bavaria、德国、86609
- 招聘中
- Novartis Investigative Site
-
Herrsching am Ammersee、Bavaria、德国、82211
- 招聘中
- Novartis Investigative Site
-
Kempten (Allgäu)、Bavaria、德国、87439
- 招聘中
- Novartis Investigative Site
-
Landsberg am Lech、Bavaria、德国、86899
- 招聘中
- Novartis Investigative Site
-
Munich、Bavaria、德国、81241
- 招聘中
- Novartis Investigative Site
-
Munich、Bavaria、德国、81377
- 招聘中
- Novartis Investigative Site
-
Regensburg、Bavaria、德国、93053
- 招聘中
- Novartis Investigative Site
-
-
Free Hanseatic City of Bremen
-
Bremerhaven、Free Hanseatic City of Bremen、德国、27576
- 招聘中
- Novartis Investigative Site
-
-
Hesse
-
Kassel、Hesse、德国、34125
- 招聘中
- Novartis Investigative Site
-
Offenbach、Hesse、德国、63065
- 招聘中
- Novartis Investigative Site
-
-
Lower Saxony
-
Goslar、Lower Saxony、德国、38642
- 招聘中
- Novartis Investigative Site
-
Rotenburg (Wümme)、Lower Saxony、德国、27356
- 招聘中
- Novartis Investigative Site
-
Twistringen、Lower Saxony、德国、27239
- 招聘中
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Cologne、North Rhine-Westphalia、德国、50674
- 招聘中
- Novartis Investigative Site
-
Cologne、North Rhine-Westphalia、德国、50677
- 招聘中
- Novartis Investigative Site
-
Cologne、North Rhine-Westphalia、德国、51103
- 招聘中
- Novartis Investigative Site
-
Solingen、North Rhine-Westphalia、德国、42653
- 招聘中
- Novartis Investigative Site
-
Wesel、North Rhine-Westphalia、德国、46483
- 招聘中
- Novartis Investigative Site
-
-
Saxony
-
Zittau、Saxony、德国、02763
- 招聘中
- Novartis Investigative Site
-
-
Saxony-Anhalt
-
Halle、Saxony-Anhalt、德国、06110
- 招聘中
- Novartis Investigative Site
-
Merseburg、Saxony-Anhalt、德国、06217
- 招聘中
- Novartis Investigative Site
-
-
Schleswig-Holstein
-
Oldenburg in Holstein、Schleswig-Holstein、德国、23758
- 招聘中
- Novartis Investigative Site
-
-
Thuringia
-
Altenburg、Thuringia、德国、04600
- 招聘中
- Novartis Investigative Site
-
Saalfeld、Thuringia、德国、07318
- 招聘中
- Novartis Investigative Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Adult Ph+ CML-CP patients, either newly diagnosed or previously treated with one ATP-competitive TKI, who initiate TKI treatment as recommended by the treating physician in a hematology center in Germany.
描述
Inclusion criteria:
- Written informed consent must be obtained before participation in the study/prior to any study-related documentation.
- Adult patients (≥18 years of age) with a confirmed diagnosis of Ph+ CML-CP. The presence of the Philadelphia chromosome may alternatively be confirmed by molecular detection of a BCR::ABL1 fusion gene/transcript (e.g., by reverse transcription polymerase chain reaction (RT-PCR)), in accordance with the World Health Organization (WHO) 2022 classification.
- Patients who are either newly diagnosed or have received treatment with exactly one prior TKI. Prior TKI treatment is only permitted for patients in the Asciminib Cohort. Patients in the comparator cohorts (imatinib, dasatinib, bosutinib, nilotinib) must be newly diagnosed and must not have received any prior TKI treatment.
- Patients for whom the treating physician has made a clinical decision to initiate treatment with asciminib or another TKI (imatinib, dasatinib, bosutinib, nilotinib) as part of routine care. The clinical decision for treatment must have been made prior to enrollment. Treatment must not have started more than 14 days before study inclusion, and treatment may also begin after baseline assessment.
- Patients willing to participate in routine follow-up visits and complete patient-reported outcome questionnaires over the course of the study.
Exclusion criteria:
-
Patients with contraindications to their respective chronic myeloid leukemia (CML) treatment as per the applicable Summary of Product Characteristics (SmPC) and relevant national treatment guidelines (e.g. Onkopedia CML), as well as additional disease- or treatment-related characteristics associated with distinct clinical scenarios that differ from the intended study population, including situations with specific treatment requirements or limited comparability, in which reliable interpretation of study outcomes may not be feasible, including the following asciminib specific considerations:
-
In first- or second-line treatment: presence of BCR::ABL1 fusion transcripts lacking exon a2 (e.g. e13a3, e14a3, e1a3).
-
In second-line treatment:
- known BCR::ABL1 mutations associated with partial or complete resistance to asciminib (e.g. M244V, F359I/V/C).
- presence of the BCR::ABL1 T315I mutation, regardless of eligibility for treatment according to SmPC (e.g., specific indication and dosing regimens).
-
-
Patients receiving or planned to receive asciminib or other TKIs outside the approved label (off-label use), including use in unapproved dosing regimens or frequency not covered by the respective SmPC.
-
Patients currently participating in an interventional clinical trial.
-
Patients unable or unwilling to provide written informed consent.
-
Patients who are unable to reliably complete patient-reported outcome questionnaires due to cognitive or language limitations relevant to the study assessments.
-
Patients for whom long-term follow-up is not feasible due to expected relocation or other logistical constraints.
-
The restriction to a maximum of one prior ATP-competitive TKI applies exclusively to patients treated with asciminib. Patients in the comparator cohorts (imatinib, dasatinib, bosutinib, nilotinib) must be TKI-naïve and are included at the start of their first-line TKI therapy and are not eligible if they have received any prior TKI treatment.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
|---|
|
Asciminib Cohort
Adult patients with Ph+ CML-CP, either newly diagnosed or previously treated with one TKI, who are treated with asciminib. |
|
Imatinib Cohort
Adult patients newly diagnosed with Ph+ CML-CP treated with imatinib who have not received any prior TKI treatment. |
|
Second-generation TKI Cohort
Adult patients newly diagnosed with Ph+ CML-CP treated with dasatinib, bosutinib, or nilotinib who have not received any prior TKI treatment. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Patients With Major Molecular Response (MMR) at 12 Months
大体时间:Month 12
|
MMR is defined as a BCR::ABL1 level ≤ 0.1% according to the International Scale (IS). |
Month 12
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
主治医生记录的TKI治疗决策原因的按患者比例
大体时间:基线
|
基线
|
|
|
按剂量减少原因划分的剂量减少患者百分比
大体时间:3、6、9、12、15、18、21和24个月
|
3、6、9、12、15、18、21和24个月
|
|
|
因治疗中断原因导致治疗中断的患者百分比
大体时间:3、6、9、12、15、18、21和24个月
|
3、6、9、12、15、18、21和24个月
|
|
|
因停药原因而停药的患者百分比
大体时间:3、6、9、12、15、18、21 和 24 个月
|
3、6、9、12、15、18、21 和 24 个月
|
|
|
治疗中止时间
大体时间:3、6、9、12、15、18、21和24个月
|
3、6、9、12、15、18、21和24个月
|
|
|
治疗中断的时间
大体时间:3、6、9、12、15、18、21和24个月
|
3、6、9、12、15、18、21和24个月
|
|
|
首次减量时间
大体时间:3、6、9、12、15、18、21和24个月
|
3、6、9、12、15、18、21和24个月
|
|
|
因不良事件终止治疗的时间(TTDAE)
大体时间:3、6、9、12、15、18、21 和 24 个月
|
3、6、9、12、15、18、21 和 24 个月
|
|
|
Percentage of Patients by Clinical Characteristic
大体时间:Baseline
|
Characteristics include, but are not limited to, detection of Philadelphia chromosome or BCR::ABL1 transcript, prior treatment, and Eastern Cooperative Oncology Group (ECOG) performance status. |
Baseline
|
|
Percentage of Patients With Early Molecular Response (EMR) at 3 Months
大体时间:Month 3
|
EMR is defined as BCR::ABL1 ≤10% IS. |
Month 3
|
|
Percentage of Patients With Molecular Response 2 (MR2)
大体时间:3, 6, 9, 12, 15, 18, 21, and 24 months
|
MR2 is defined as BCR::ABL1 ≤1% IS. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Percentage of Patients With MMR
大体时间:3, 6, 9, 15, 18, 21, and 24 months
|
MMR is defined as BCR::ABL1 ≤0.1% IS. |
3, 6, 9, 15, 18, 21, and 24 months
|
|
Percentage of Patients With Deep Molecular Response: MR4.0
大体时间:3, 6, 9, 12, 15, 18, 21, and 24 months
|
Deep Molecular Response (MR4.0): ≤0.01% BCR::ABL1 IS and Reference gene copies >10,000 ABL1 or >24,000 GUSB. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Percentage of Patients With Deep Molecular Response: MR4.5
大体时间:3, 6, 9, 12, 15, 18, 21, and 24 months
|
Deep Molecular Response (MR4.5): ≤0.0032% BCR::ABL1 IS and Reference gene copies >32,000 ABL1 or >77,000 GUSB. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Percentage of Patients With Deep Molecular Response: MR5
大体时间:3, 6, 9, 12, 15, 18, 21, and 24 months
|
Deep Molecular Response (MR5): ≤0.001% BCR::ABL1 IS and Reference gene copies >100,000 ABL1 or >240,000 GUSB. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Medication Adherence Report Scale (MARS-5) Score
大体时间:3, 6, 9, 12, 15, 18, 21, and 24 months
|
The MARS-5 questionnaire is a validated self-report questionnaire developed to assess patient adherence to prescribed medication, focusing on both intentional and unintentional non-adherence. It consists of 5 items, each rated on a 5-point Likert Scale from 0 (always) to 5 (never). The total score ranges from 5 to 25, with higher scores indicating better adherence to treatment. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Score
大体时间:3, 6, 9, 12, 15, 18, 21, and 24 months
|
The EORTC QLQ-C30 contains 30 questions answered by the patient. There are 9 multiple-item scales: 5 scales that assess aspects of functioning (physical, role functioning, cognitive, emotional, and social); 3 symptom scales (fatigue, pain, and nausea and vomiting); and a global health status/Quality of Life (QOL) scale. There are 5 single-item measures assessing additional symptoms (i.e., dyspnea, loss of appetite, insomnia, constipation, and diarrhea) and a single item concerning perceived financial impact of the disease. All but 2 questions have 4-point scales ranging from "Not at all" to "Very much." The 2 questions concerning global health status/QOL have 7-point scales with ratings ranging from "Very poor" to "Excellent." For each of the 14 domains, final scores are transformed such that they range from 0-100, where higher scores indicate improvement. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for CML (EORTC QLQ-CML24) Score
大体时间:3, 6, 9, 12, 15, 18, 21, and 24 months
|
The EORTC QLQ-CML24 was designed to supplement the QLQ-C30 - the QLQ-CML24 is not a stand-alone instrument but is to be used in conjunction with the QLQ-C30. The EORTC QLQ-CML24 is composed of 4 multi-item scales and 2 single-item scales. The module consists of 24 items assessing symptom burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items are measured on 4 levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each domain, scores are averaged and transformed to 0 to 100. A higher score in symptom burden, impact on worry/mood, impact on daily life, and body image problems domains indicates a worse outcome. A higher score in satisfaction with social life and satisfaction with care and information domains indicates a higher level of satisfaction. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Work Productivity and Activity Impairment - General Health (WPAI-GH) Score
大体时间:3, 6, 9, 12, 15, 18, 21, and 24 months
|
The WPAI-GH is a patient-reported 6 item questionnaire which addresses absenteeism, presenteeism, overall work productivity loss, and activity impairment for the 7 days prior to the assessment. Work productivity and activity impairment outcomes are presented as impairment percentages ranging from 0 to 100 with a higher percentage indicating greater impairment and less productivity. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
合作者和调查者
调查人员
- 研究主任:Novartis Pharmaceuticals、Novartis Pharmaceuticals
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- CABL001J1DE02
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.